Targeted Therapy of IDH1-Mutated Tumors

IDH1 and IDH2 are homodimeric enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) as part of the TCA cycle. Mutations in the genes encoding IDH1 and IDH2 have recently been found in glioma, acute myeloid leukemia (AML), chondrosarcoma, and intrahepatic cholangiocarcinoma. Th...

Full description

Saved in:
Bibliographic Details
Published inMalignant Brain Tumors pp. 151 - 161
Main Authors Clark, Owen, Grommes, Christian
Format Book Chapter
LanguageEnglish
Published Switzerland Springer International Publishing AG 2017
Springer International Publishing
Subjects
2-hydroxyglutarate (2-HG)
Acute myeloid leukemia (AML)
Differentiation
IDH1
IDH2
Low-grade glioma
Neurosurgery
Oncometabolite
Surgical oncology
Online AccessGet full text

Cover

More Information
Summary:IDH1 and IDH2 are homodimeric enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) as part of the TCA cycle. Mutations in the genes encoding IDH1 and IDH2 have recently been found in glioma, acute myeloid leukemia (AML), chondrosarcoma, and intrahepatic cholangiocarcinoma. The mutant protein loses its normal enzymatic activity and gains a new ability to produce the ‘oncometabolite’ 2-hydroxyglutarate (R-2-HG). R-2-HG inhibits enzymes that play crucial roles in gene regulation and tissue homeostasis. Expression of mutant IDH impairs cellular differentiation in various cell lineages and promotes tumor development in cooperation with other cancer genes. First-generation inhibitors of mutant IDH have entered clinical trials and have shown encouraging results in patients with IDH-mutant AML. This chapter summarizes recent progress in our understanding of the role of mutant IDH in tumorigenesis.
ISBN:3319498630
9783319498638
DOI:10.1007/978-3-319-49864-5_10